Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

NSAIDs: The Heart of the Controversy

Kurt Ullman  |  Issue: June 2007  |  June 1, 2007

Another concern is that “the statement does not take into account the differences between the musculoskeletal conditions for which these agents might be used or the diversity of biological effects of the COX-1– and COX-2–derived prostaglandins that may affect other organ systems,” says Dr. Crofford. “The way the statement was put together from a specific cardiovascular risk-focused perspective did not adequately capture the diversity of conditions [we see] that would need different types of therapy and also the diversity of personal risks seen in our patients.”

Bottom Line: Balance Benefit and Risk

Dr. Crofford suggests that physicians need to realistically evaluate drug risks in the specific patient before them.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The bottom line is that there has to be a balance in the risk–benefit ratio, the patient has to be informed, and the physician has to be knowledgeable,” she says. “If these criteria are met, I am in favor of giving patients and physicians choices of drugs.”

Kurt Ullman is a freelance writer based in Indiana.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References:

  1. Antman EM, Bennet JS, Daughtery A, et al. Use of nonsteroidal anti-inflammatory drugs: An update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-1642.
  2. Callahan LF, Pincus T. Mortality in the rheumatic diseases. Arthritis Care Res. 1995;8:229-241.

Guidelines for the Perplexed, Or how I lost my poetic license but not my medical license

By David Fox, MD

Now, as you know, with the drug hydralazineSome cases of lupus are now and then seen. So should rheumatologists hold a convention To promulgate guidelines about hypertension?

Wait! Before you might answer, consider the statin, That cute little pill that will lower the fat in Your arteries cardiac—yet there’s a fuss all Because this same statin can inflame your muscle!

Would it therefore not be especially sensible, Indeed, one could even suggest, indispensable, To have ACR guidelines on lowering lipid? Or would this sort of venture instead be insipid?

Now here come our friends from American Heart, Eager, as always, to play a big part, In telling us all how we should treat arthritis, Rheumatoid, osteo-, even bursitis.1

Great experts are they as they quickly will tell us, And their wise advice now is designed to propel us To change how we treat the diseases rheumatic, To avoid any more cardiology static.

“It’s RA! Well, goodness, do not use an NSAID, Until you have tried heat and cold—even rest in bed. If you say ‘pretty please’ we’ll allow a naproxen, Even though those who get it might then need digoxin!

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:AnalgesicsDrug Updates Tagged with:AC&RdosageNonsteroidal anti-inflammatory drugs (NSAIDs)patient carerheumatologistSafetyside effect

Related Articles
    A Comprehensive Review of NSAID Cardiovascular Toxicity

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    July 18, 2018

    Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

    The Why & What of the ACR's Clinical Practice Guidelines

    The Why & What of the ACR’s Clinical Practice Guidelines

    February 18, 2018

    With the support of its membership, the ACR publishes clinical practice guidelines in multiple disease areas based on the best available clinical and scientific data. These aim to support health professionals treating rheumatology patients to give the best possible care. Like any set of medical guidelines, ACR guidelines are based on evidence of several different…

    Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients

    February 16, 2021

    In a controlled, large-cohort, longi­tudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1  This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…

    Why Tweaking Molecular Structures Can Be Hazardous to Our Health

    June 1, 2014

    The rise and fall of rofecoxib and valdecoxib demonstrate the need for caution in new drug development

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences